CytoMed Therapeutics (GDTC) Receivables - Net (2021 - 2025)
CytoMed Therapeutics (GDTC) posted Receivables - Net of $80135.3 for Q4 2025, down 93.48% sequentially from $1.2 million in Q2 2025, and down 89.65% YoY from $774582.3 in Q4 2024.
CytoMed Therapeutics (GDTC) Receivables - Net (2021 - 2025) Analysis & Trends
CytoMed Therapeutics has reported Receivables - Net for 5 years, with the latest figure at $80135.3 in Q4 2025.
- Quarterly Receivables - Net fell 89.65% year-over-year to $80135.3 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $80135.3 (down 89.65% YoY) and the FY2025 annual result came in at $1.2 million, up 58.04% from the prior year.
- Receivables - Net eased to $80135.3 in Q4 2025 per GDTC's latest filing, from $1.2 million in the prior quarter.
- Over five years, Receivables - Net peaked at $1.2 million in Q2 2025 and troughed at $9805.0 in Q2 2024.
- A 5-year average of $446093.1 and a median of $323392.3 in 2021 frame the typical range for Receivables - Net.
- The sharpest annual moves came in 2022 and 2025: Receivables - Net slumped 90.7% in 2022, then jumped 12426.16% in 2025.
- Over 5 years, Receivables - Net stood at $566649.2 in 2021, then plunged by 90.7% to $52704.8 in 2022, then surged by 1448.1% to $815920.1 in 2023, then slipped by 5.07% to $774582.3 in 2024, then sank by 89.65% to $80135.3 in 2025.
- According to Business Quant data, Receivables - Net over the past three periods registered $80135.3, $1.2 million, and $774582.3 for Q4 2025, Q2 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.76 Bn | 131.91 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.51 Bn | 78.51 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.74 Bn | 60.56 Bn | 1.37 Bn |
| 4 | Moderna | 59.39 Bn | 54.26 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.24 Bn | 37.15 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.78 Bn | 28.47 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.65 Bn | 10.26 Bn | 668.28 Mn |
| 8 | Insmed | 27.58 Bn | 26.42 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.22 Bn | 26.39 Bn | - |
| 10 | CytoMed Therapeutics | 9.97 Mn | 8.35 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 80,135.32 |
| Dec 31, 2025 | 80,135.32 |
| Jun 30, 2025 | 1.23 Mn |
| Jun 30, 2025 | 1.23 Mn |
| Dec 31, 2024 | 774,582.34 |
| Dec 31, 2024 | 774,582.34 |
| Jun 30, 2024 | 9,805.00 |
| Jun 30, 2024 | 9,805.00 |
| Dec 31, 2023 | 815,920.15 |
| Dec 31, 2023 | 815,920.15 |
| Jun 30, 2023 | 40,758.00 |
| Jun 30, 2023 | 40,758.00 |
| Dec 31, 2022 | 52,704.78 |
| Dec 31, 2022 | 52,704.78 |
| Dec 31, 2021 | 566,649.22 |
| Dec 31, 2021 | 566,649.22 |